Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Key Inclusion Criteria:

- Judged to be healthy by the Investigator on the basis of medical history, physical
examination and vital signs performed at Screening;

- Able and willing to comply with all study procedures;

- Screening laboratory results within normal limits;

- Negative tests for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody and Human
Immunodeficiency Virus (HIV) antibody;

- Screening electrocardiogram (ECG) deemed by the Investigator as having no clinically
significant findings (e.g. Wolff-Parkinson-White syndrome);

- Be post-menopausal or be surgically sterile or have a partner who is sterile or use
medically effective contraception with a failure rate of < 1% per year when used
consistently and correctly from screening until 3 months following last dose.

Key Exclusion Criteria:

- Pregnant or breastfeeding, or intending to become pregnant or father children within
the projected duration of the trial starting with the screening visit until 3 months
following last dose;

- History of respiratory diseases such as asthma, chronic obstructive pulmonary disease
(COPD) or chronic bronchitis;

- Currently participating in or has participated in a study with an investigational
product within 30 days preceding Day 0;

- Previous receipt of any vaccine within 30 days preceding Day 0 or planning to receive
any vaccine during the timeframe restricted per the protocol;

- Previous receipt of an investigational vaccine product for the prevention of MERS;

- Prior exposure to MERS-CoV or camels;

- Participants who participate in MERS-201 Part 1 cannot participate in MERS-201 Part 2;

- Fewer than two acceptable sites available for ID injection and EP considering the
deltoid and anterolateral quadriceps muscles;

- Prisoner or participants who are compulsorily detained (involuntary incarceration);

- Current or anticipated concomitant immunosuppressive therapy (excluding inhaled,
topical skin and/or eye drop-containing corticosteroids) prior to dosing. Systemic
corticosteroids must be discontinued at least 3 months prior to first dose;

- Reported active drug or alcohol or substance abuse or dependence.